Abstract: Compounds of formula (I): wherein R1 represents a hydrogen atom or a heterocyclic, cyano, alkoxycarbonyl, alkylsulphonylaminoalkyl or N-hydroxycarboximidamide group. Medicinal products containing the same which are useful as modulators of the AMPA receptor.

Abstract: Compounds of formula: wherein: ALK represents an alkylene chain, W represents a group wherein R and R? are as defined in the description. Medicinal products containing the same which are useful in treating cognitive disorders associated with cerebral aging or with neurodegenerative diseases.

Abstract: Compounds of formula (I): wherein: R1 and R2, which may be the same or different, each represent a hydrogen or halogen atom or an alkyl, alkoxy, alkylthio, acyl, alkoxycarbonyl, carboxy, hydroxy, hydroxyalkyl, cyano, nitro, amino, substituted or unsubstituted aminocarbonyl, aminosulphonyl, alkylsulphonylaminoalkyl, N-hydroxy-carboximidamide or benzyloxy group, R3 represents a hydrogen atom or an alkyl, cycloalkyl or cycloalkylalkyl group, R4 represents a hydrogen atom or a substituted or unsubstituted alkyl group Medicinal products containing the same which are useful in treating or preventing conditions treatable by an AMPA receptor modulator and/or an NMDA receptor antagonist.

Abstract: Compounds of formula (I): wherein R1 represents a hydrogen atom or a heterocyclic, cyano, alkoxycarbonyl, alkylsulphonylaminoalkyl or N-hydroxycarboximidamide group. Medicinal products containing the same which are useful as modulators of the AMPA receptor.

Abstract: Compounds of formula (I): wherein: ALK represents an alkylene chain, W represents a group wherein R and R? are as defined in the description. Medicinal products containing the same which are useful in the treatment of conditions associated with central histaminergic systems.

Abstract: Compounds of formula (I): wherein: ALK represents an alkylene chain, W represents a group wherein R and R? are as defined in the description. Medicinal products containing the same which are useful in the treatment of conditions associated with central histaminergic systems.

Abstract: Compounds of formula (I): wherein: ALK represents an alkylene chain, W represents a group selected from wherein R and R? are as defined in the description. Medicinal products containing the same which are useful in the treatment of cognitive and psycho-behavioural disorders associated with cerebral ageing, with neurodegenerative diseases or with cranial traumas and also in the treatment of mood disorders, of schizophrenia and of cognitive disorders associated therewith, of sleep disorders, of sleep-waking rhythm disorders, of attention-deficit hyperactivity syndrome or of obesity.

Abstract: Compounds of formula (I): wherein: R1 represents a hydrogen atom or a methyl group, R2 represents a bromine atom, a fluorine atom or a trifluoromethyl group. Medicinal products containing the same which are useful in treating cognitive disorders associated with pathologies of the central nervous system.

Abstract: Compounds of formula (I): wherein: n represents an integer of from 1 to 6 inclusive, X represents an oxygen atom or an NR6 group, Y represents a carbon atom or a nitrogen atom, Z represents a carbon atom or a nitrogen atom, R1 and R2 represent a hydrogen atom or an alkyl or arylalkyl group, R3 and R4 represent a hydrogen atom or an alkyl group, R5 represents a hydrogen atom or an alkyl, halogen, hydroxy, alkoxy, cyano, nitro, acyl, alkoxycarbonyl, trihaloalkyl, trihaloalkoxy or optionally substituted amino group, R6 represents a hydrogen atom or an alkyl or arylalkyl group, Ra, Rb, Rc, Rd and Re are as defined in the description. Medicinal products containing the same which are useful as specific nicotinic ligands of ?4?2 receptors.

Abstract: Compounds of formula (I): wherein: R1 and R2, which may be the same or different, each represent a hydrogen or halogen atom or an alkyl, alkoxy, alkylthio, acyl, alkoxycarbonyl, carboxy, hydroxy, hydroxyalkyl, cyano, nitro, amino, substituted or unsubstituted aminocarbonyl, aminosulphonyl, alkylsulphonylaminoalkyl, N-hydroxy-carboximidamide or benzyloxy group, R3 represents a hydrogen atom or an alkyl, cycloalkyl or cycloalkylalkyl group, R4 represents a hydrogen atom or a substituted or unsubstituted alkyl group Medicinal products containing the same which are useful in treating or preventing conditions treatable by an AMPA receptor modulator and/or an NMDA receptor antagonist.

Abstract: Compounds of formula (I): wherein: RCy represents an unsubstituted or substituted cycloalkyl group or cycloalkylalkyl group, R1, R2, R3 and R4, which may be the same or different, each represent a hydrogen or halogen atom or a nitro group; a cyano group; a hydroxy group; an alkoxy group; an alkyl group; an unsubstituted or substituted amino group; a carboxy group; an alkoxycarbonyl group; an aryloxycarbonyl group; an unsubstituted or substituted aminocarbonyl group. Medicinal products containing the same which are useful in treating or preventing conditions treatable by an AMPA receptor modulator.

Abstract: Compounds of formula (I): wherein: RCy represents an unsubstituted or substituted cycloalkyl group or cycloalkylalkyl group, R1, R2, R3 and R4, which may be the same or different, each represent a hydrogen or halogen atom or a nitro group; a cyano group; a hydroxy group; an alkoxy group; an alkyl group; an unsubstituted or substituted amino group; a carboxy group; an alkoxycarbonyl group; an aryloxycarbonyl group; an unsubstituted or substituted aminocarbonyl group. Medicinal products containing the same which are useful in treating or preventing conditions treatable by an AMPA receptor modulator.

Abstract: Compounds of formula (I): wherein: ALK represents an alkylene chain, W represents a group selected from wherein R and R? are as defined in the description. Medicinal products containing the same which are useful in the treatment of cognitive and psycho-behavioural disorders associated with cerebral ageing, with neurodegenerative diseases or with cranial traumas and also in the treatment of mood disorders, of schizophrenia and of cognitive disorders associated therewith, of sleep disorders, of sleep-waking rhythm disorders, of attention-deficit hyperactivity syndrome or of obesity.

Abstract: A compound selected from those of formula (I): wherein m and n, which may be identical or different, each represent an integer from 0 to 2 inclusive, with the sum of the two integers being from 2 to 3 inclusive, p and q, which may be identical or different, each represent an integer from 0 to 2 inclusive, Alk represents an alkylene, alkenylene or alkynylene chain, X represents an oxygen atom, a sulphur atom or an —N(R)— group wherein R represents a hydrogen atom or an alkyl group, Y, Y? and W are as defined in the description, its enantiomers, diastereoisomers, and addition salts thereof with one or more pharmaceutically acceptable acid or base. Medicinal products containing the same which are useful for treating conditions associated with central histaminergic systems.

Abstract: A compound selected from those of formula (I): wherein: X represents a C(O) or SO2 group, R1 represents an aryl group or a group NR3R4 wherein R3 and R4 are as defined in the description, R2 represents an alkyl, (C3-C8)cycloalkyl or (C3-C8)cycloalkyl-(C1-C6)alkyl group, its isomers, and addition salts thereof, and medicinal products containing the same which are useful in treating conditions treatable by antagonists of type H3 central histamine receptors.

Abstract: A compound selected from those of formula (I): wherein: R1 represents an NR3SO2R4 group wherein: R3 represents a hydrogen atom or an alkyl group, R4 represents an alkyl group, aryl group or NR5R6 group, R2 represents an alkyl, cycloalkyl or cycloalkylalkyl group, and medicinal products containing the same which are useful in treating conditions treatable by antagonists of type H3 central histamine receptors.

Abstract: Compounds of formula (I): wherein: A represents thienyl, furyl, pyrrolyl, oxathiol, thiazole, isothiazole, oxazole or imidazole, represents a single bond or a double bond, R1 represents hydrogen, linear or branched (C1-C6)alkyl optionally substituted by one or more groups selected from halogen or (C1-C6)alkoxy-(C1-C6)alkyl, R2 represents hydrogen or linear or branched (C1-C6)alkyl group optionally substituted by one or more halogen, R3 represents hydrogen or a group selected from linear or branched (C1-C6)alkyl, CONHR? and SO2NHR? wherein R? represents linear or branched (C1-C6)alkyl, its enantiomers and diastereoisomers, and addition salts thereof with a pharmaceutically acceptable acid or base. Medicinal products containing the same, which are useful as AMPA inhibitors.

Abstract: Compounds of formula (I): wherein: R1 represents hydrogen, a halogen or alkyl, R1a represents hydrogen or alkyl, R2 represents hydrogen, a halogen or hydroxy, A represents NR4, R3 represents hydrogen, alkyl or cycloalkyl, R4 represents hydrogen or alkyl, X is as defined in the description, their isomers, and also addition salts thereof. Medicinal products containing the same which are useful in treating disorders of the AMPA system.

Abstract: A compound selected from those of formula (1): wherein: n represents an integer from 1 to 6 inclusive, R1 and R2 represent a hydrogen atom, a (C1-C6)alkyl group or an aryl-(C1-C6)alkyl group, R3 and R4 represent a hydrogen atom or a (C1-C6)alkyl group, R5 and R6 represent a hydrogen atom or a (C1-C6)alkyl, halogen, hydroxy, (C1-C6)alkoxy, cyano, nitro, (C2-C6)acyl, (C1-C6)alkoxycarbonyl, (C1-C6)trihaloalkyl or (C1-C6)-trihaloalkoxy group or an optionally substituted amino group, R7 represents a hydrogen atom, a (C1-C6)alkyl group or an arylalkyl group, its enantiomers, diastereoisomers and additional salts thereof with a pharmaceutically acceptable acid or base. Medicinal products containing the same which are useful in the treatment of conditions requiring a specific nicotinic ligand of ?4?2 receptors.

Abstract: A compound selected from those of formula (I): wherein: n represents an integer from 1 to 6 inclusive, R1 and R2 represent a hydrogen atom, a (C1-C6)alkyl group or an aryl-(C1-C6)alkyl group, R3 and R4 represent a hydrogen atom or a (C1-C6)alkyl group, R5 and R6 represent a hydrogen atom or a (C1-C6)alkyl, halogen, hydroxy, (C1-C6)alkoxy, cyano, nitro, (C2-C6)acyl, (C1-C6)alkoxycarbonyl, (C1-C6)trihaloalkyl or (C1-C6)-trihaloalkoxy group or an optionally substituted amino group, R7 represents a hydrogen atom, a (C1-C6)alkyl group or an arylalkyl group, its enatiomers, diastereoisomers and additional salts thereof with a pharmaceutically acceptable acid or base. Medicinal products containing the same which are useful in the treatment of conditions requiring a specific nicotinic ligand of ?4?2 receptors.